The Preventive and Therapeutic Potential of the Flavonoids in Liver Cirrhosis: Current and Future Perspectives

Non‐alcoholic fatty liver disease (NAFLD) may vary from moderately mild non‐alcohol fatty liver (NAFL) towards the malignant variant known as non‐alcoholic steatohepatitis (NASH), which is marked by fatty liver inflammation and may progress to liver cirrhosis (LC), liver cancer, fibrosis, or liver failure. Flavonoids can protect the liver from toxins through their anti‐inflammatory, antioxidant, anti‐cancer, and antifibrogenic pharmacological activities. Furthermore, flavonoids protect against LC by regulation of hepatic stellate cells (HSCs) trans‐differentiation, inhibiting growth factors like TGF‐β and platelets‐derived growth factor (PDGF), vascular epithelial growth factor (VEGF), viral infections like hepatitis‐B, C and D viruses (HBV, HCV & HDV), autoimmune‐induced, alcohol‐induced, metabolic disorder‐induced, causing by apoptosis, and regulating MAPK pathways. These flavonoids may be explored in the future as a therapeutic solution for hepatic diseases.